CD4 and neoplasm: KVax and KVax plus CA170 (Combo) treatments increased tumor-infiltrating CD4+ T cells compared to adjuvant controls (Fig. 2A, upper and lower right panels), whereas no difference was observed in the CA170 alone treatment group.